Blocking is a critical step for controlling nonspecific background in immunoassays such as Western Blot, ELISA, IHC, and IF, but the targets of blocking are not completely identical among different experiments. BSA, Casein, and protein-free blocking solutions are mainly used to limit nonspecific adsorption of antibodies or proteins on membranes, microplates, and tissue surfaces, whereas endogenous peroxidase and alkaline phosphatase blocking specifically target intrinsic tissue enzyme activity.

Keywords: immunoassay blocking; Western Blot; ELISA; IHC; BSA; protein-free blocking; endogenous peroxidase

1 Blocking in Immunoassays

1.1 Sources of Nonspecific Binding

Western Blot membranes, ELISA microplates, and fixed tissue or cell surfaces all contain binding regions not occupied by the target protein. Antibodies, enzyme-labeled conjugates, and other proteins in samples can bind to these regions through hydrophobic interactions, electrostatic interactions, or nonspecific protein interactions, producing membrane background, nonspecific bands, elevated blank wells, or nonspecific tissue staining. The basic function of blocking is to preoccupy or mask these non-target binding sites and improve discrimination between specific signal and background.

1.2 Sources of Endogenous Background

In enzyme-based chromogenic assays such as IHC, background can arise not only from nonspecific antibody binding but also from endogenous tissue Peroxidase or Alkaline Phosphatase activity. In HRP-DAB systems, endogenous peroxidase can directly catalyze substrate conversion and produce chromogenic deposits. In AP chromogenic systems, endogenous tissue alkaline phosphatase can likewise generate nonspecific signals. Therefore, these backgrounds require dedicated endogenous enzyme-blocking systems.

1.3 Major Types of Blocking Systems

(1) Protein-Based Blocking

Proteins such as BSA and Casein competitively occupy nonspecific binding sites on solid surfaces or membranes and are established blocking approaches in WB and ELISA.

(2) Protein-Free Blocking

Protein-free blocking systems do not rely on large amounts of exogenous proteins for site occupation. They can reduce potential cross-reactivity between blocking proteins such as BSA or Casein and detection antibodies and are suitable for some high-sensitivity detection systems.

(3) Immunostaining Blocking

Dedicated blocking solutions for IHC, IF, and ICC are used to reduce nonspecific binding of antibodies to tissue or cellular components. Their use needs to be designed together with fixation, antigen retrieval, permeabilization, and antibody-dilution conditions.

(4) Endogenous Enzyme Blocking

Endogenous Peroxidase and Alkaline Phosphatase blocking target intrinsic tissue catalytic activity, which is completely different from the target of conventional protein blocking and cannot be replaced by BSA, Casein, or protein-free blocking solutions.

Table 1 Major Blocking Types in Immunoassays

2 Protein-Based Blocking Systems

2.1 BSA Blocking

(1) Functional Characteristics

Bovine Serum Albumin (BSA) can cover unoccupied regions on PVDF and NC membranes and polystyrene microplates, reducing nonspecific adsorption of primary antibodies, secondary antibodies, and enzyme-labeled conjugates. BSA has a relatively simple composition and is therefore suitable for experiments requiring greater control over blocking-agent composition.

(2) Major Advantages

BSA is suitable for routine WB and ELISA and is also one of the commonly preferred blocking systems for phosphoprotein Western Blot. Compared with systems such as Casein that contain more phosphorylated protein components, BSA has relatively less potential interference with some Phospho-specific Antibodies.

(3) Major Limitations

BSA itself is a bovine-derived protein. When detecting BSA, Albumin, or using antibodies that may recognize bovine proteins, additional background may occur. Excessively high BSA concentrations may also reduce effective signals from some low-abundance targets, so blocking-agent concentration should not simply be set according to the principle of “the higher, the better.”

2.2 Casein Blocking

(1) Functional Characteristics

Casein has strong surface-adsorption capacity and can effectively cover hydrophobic binding sites on microplates and membranes. Its major value in ELISA and routine immunoblotting is to reduce nonspecific protein binding to solid-phase carriers.

(2) Major Advantages

Casein provides good coverage of high-binding microplates and some high-background immunoassay systems and can provide strong blocking effects in routine ELISA and non-phosphoprotein WB.

(3) Major Limitations

Casein is a phosphoprotein system and may interfere with detection by some phosphorylation-site-specific antibodies. Therefore, Phospho-protein Western Blot generally should not use Casein without prior validation. Its protein composition is also more complex than that of high-purity BSA and is not suitable for assays requiring strict avoidance of exogenous protein interference.

Table 2 Comparison of BSA and Casein Blocking Systems

3 Protein-Free and Rapid Blocking Systems

3.1 Protein-Free Blocking

(1) Functional Characteristics

Protein-free blocking systems reduce nonspecific binding to membranes, microplates, or other solid-phase carriers through non-protein components and do not rely on large quantities of proteins such as BSA, Casein, or milk powder for site occupation.

(2) Major Advantages

Protein-free systems can avoid recognition of the blocking protein itself by detection antibodies and are particularly suitable for detection of BSA, Casein, and other related protein targets. They are also applicable to some high-sensitivity immunoassays that require reduced lot-to-lot variation from protein components.

(3) Major Limitations

Different PVDF and NC membranes, microplates, and antibodies vary in compatibility with protein-free blocking agents. For some highly hydrophobic backgrounds or specific antibody systems, conventional BSA or Casein may still provide a higher Signal-to-Background Ratio. Therefore, parallel comparison is required after changing the blocking agent.

3.2 Rapid Blocking

Rapid blocking systems shorten blocking time mainly by optimizing blocking components and interface interactions and are suitable for experiments requiring improved WB or immunoassay turnaround efficiency. When evaluating rapid blocking systems, target-band intensity, nonspecific bands, membrane background, and experimental reproducibility should be assessed together rather than comparing blocking time alone.

3.3 Concentrated Blocking Solutions

5× or 10× concentrated blocking solutions are convenient for batch experiments and preparation of working solutions, but their performance depends on correct dilution. Changes in working concentration affect not only blocking strength but may also alter salt concentration, buffering capacity, and surfactant levels. Therefore, they should be prepared according to the specified dilution ratio for the corresponding product.

4 PBS-, TBS-, and Surfactant-Based Blocking Systems

4.1 PBS Systems

PBS maintains a buffered environment through phosphate salts and has stable ionic composition, making it suitable for most routine WB, ELISA, and immunostaining assays. Its major advantage is broad applicability, but in phosphate-sensitive enzymatic or specialized reactions, the suitability of PBS as the basal buffer needs to be evaluated.

4.2 TBS Systems

TBS uses Tris as the major buffering system and contains no phosphate. It is commonly used in Western Blot and immunoassays where phosphate interference needs to be reduced. For some phosphoproteins and specific antibody systems, TBS/TBST can be prioritized for validation, although whether it is superior to PBS still needs to be determined according to the actual Signal-to-Background Ratio.

4.3 Systems Containing Mild Surfactants

Systems such as PBSTw and TBSTw contain nonionic surfactant components in the basal buffer and can reduce hydrophobic nonspecific adsorption between antibodies and membranes or solid surfaces. These systems are suitable for WB membrane washing, ELISA washing, and some antibody incubations, although excessive surfactant activity may also reduce signals from weak-affinity antibodies.

4.4 Permeabilizing Surfactant Systems

Systems such as PBSTx and TBSTx have surfactant characteristics distinct from simple basal buffers and are more suitable for immunostaining systems requiring simultaneous consideration of membrane permeabilization and background control. For membrane proteins or soluble proteins that are readily lost, surfactant conditions need to be carefully optimized to avoid excessive permeabilization affecting target preservation.

Table 3 Selection Characteristics of Different Buffer-Based Blocking Systems

5 Selection of Blocking Systems for Western Blot

5.1 Routine Total-Protein WB

Routine Western Blot can use BSA, Casein, milk powder-based blockers, WB-specific blocking solutions, or protein-free systems. Selection should simultaneously consider membrane type, antibody background, and target-protein abundance. When conventional blocking already produces clear bands, there is no need to simply increase blocking-agent concentration or extend blocking time.

5.2 Phosphoprotein WB

Phosphorylation-specific antibodies are generally more sensitive to blocking-agent composition. Because systems such as Casein contain phosphorylated protein components, phosphoprotein detection usually prioritizes validation of BSA or protein-free blocking systems together with TBS/TBST-based buffer conditions to reduce potential interference.

5.3 Low-Abundance Proteins

Experiments targeting low-abundance proteins need to focus on improving the Signal-to-Background Ratio. Excessive blocking may reduce background while simultaneously weakening the effective signal. Therefore, target-band intensity, background, nonspecific bands, and exposure dynamic range need to be evaluated comprehensively.

5.4 High-Background Antibodies

High background is not necessarily caused by insufficient blocking. Excessive primary antibody concentration, secondary antibody cross-reactivity, insufficient membrane washing, and poor intrinsic antibody specificity can all produce similar phenomena. Therefore, when changing among BSA, Casein, or protein-free blockers, antibody concentrations and washing conditions should be optimized simultaneously.

6 Selection of Blocking Systems for ELISA

6.1 Unoccupied Regions of Microplates

After antigen or capture antibody coating in ELISA, large numbers of unoccupied protein-adsorption regions remain on the microplate surface. Blocking agents cover these sites and limit direct adsorption of sample proteins, detection antibodies, and enzyme-labeled conjugates to the plate surface, thereby reducing Blank and Negative Control background.

6.2 BSA-Based ELISA Blocking

BSA systems have relatively defined composition and are suitable for routine indirect ELISA and sandwich ELISA. Their major limitation is that background may occur when detecting BSA, bovine Albumin, or related antibodies. Such assays are therefore more suitable for protein-free or alternative blocking systems.

6.3 Casein-Based ELISA Blocking

Casein has strong plate-surface coverage capacity and is suitable for high-binding microplates and some high-background ELISAs. In complex antibody systems, Blank wells, negative controls, and standard curves should be used to evaluate whether additional nonspecific reactions occur.

6.4 Synthetic and Dedicated ELISA Blocking Solutions

Dedicated ELISA blocking solutions can reduce lot-to-lot variation caused by self-prepared protein blockers. Protein-free synthetic blocking systems further avoid cross-reactivity with exogenous proteins. Selection should compare Blank OD, low-concentration standard signals, standard-curve slope, and reproducibility rather than observing only color intensity in high-concentration wells.

Table 4 Selection of ELISA Blocking Systems

7 Nonspecific Blocking in IHC and IF

7.1 IHC Blocking

Nonspecific background in IHC can arise from non-target binding of antibodies to tissue proteins, charged structures, or Fc receptors. Dedicated immunostaining blocking solutions mainly address this type of nonspecific antibody binding but cannot replace antigen retrieval, Fc receptor blocking, or endogenous enzyme blocking.

7.2 IF Blocking

IF does not rely on HRP- or AP-catalyzed chromogenic reactions. Its major background sources include nonspecific antibody binding, fluorescent secondary-antibody cross-reactivity, and tissue autofluorescence. Conventional immunostaining blocking solutions can reduce nonspecific antibody binding but cannot directly eliminate autofluorescence generated by Lipofuscin, heme, and related substances.

7.3 Fc Receptor Blocking

Immune cells and some myeloid cells highly express Fc receptors, and the Fc region of antibodies can bind these receptors and generate nonspecific signals. Fc receptor blocking reagents act at a different level from conventional BSA or protein-free blocking and have independent value in flow cytometry, immune-cell staining, and studies of tissues rich in immune cells.

8 Endogenous Peroxidase Blocking

8.1 Endogenous Peroxidase Background

HRP-DAB systems use HRP to catalyze substrate conversion and generate colored deposits, but erythrocytes, granulocytes, and some tissues themselves have Peroxidase-like activity. If these activities are not sufficiently suppressed, nonspecific chromogenic signals may appear even in the absence of target antigen–antibody binding.

8.2 Conventional Peroxidase Blocking

Conventional endogenous peroxidase blocking solutions are suitable for most HRP-IHC procedures and balance reduction of endogenous tissue enzyme background with preservation of tissue antigens. Whether they are required depends on the downstream detection system and tissue type; they are not necessary in every IHC or IF experiment.

8.3 Strong Peroxidase Blocking

Strong blocking systems are suitable for tissues rich in blood, containing large numbers of myeloid cells, or showing substantial Peroxidase background after conventional treatment. Greater blocking capacity does not mean that strong conditions should be applied to all samples. The requirement should be determined together with no-primary-antibody controls and tissue background.

9 Endogenous Alkaline Phosphatase Blocking

9.1 Sources of AP Background

In AP chromogenic systems, tissues such as intestine, kidney, and bone with high endogenous Alkaline Phosphatase activity may directly catalyze chromogenic substrates and generate background. Dedicated blocking systems targeting endogenous AP activity are therefore required.

9.2 Differences Between HRP and AP Blocking

Peroxidase blocking targets Peroxidase, whereas alkaline phosphatase blocking targets Alkaline Phosphatase, and the two cannot substitute for each other. The blocking type should first be determined according to the Detection Enzyme, followed by selection of treatment intensity according to endogenous enzyme activity in the specific tissue.

10 Experimental Interpretation of Blocking Effects

10.1 Background Reduction Accompanied by Decreased Target Signal

When blocking-agent concentration is too high, treatment time is too long, or the blocker is incompatible with the antibody system, both nonspecific background and target signal may decrease. Blocking optimization should therefore focus on the Signal-to-Background Ratio rather than simply pursuing the lowest possible background.

10.2 Persistent Nonspecific Bands in WB

If nonspecific bands persist after changing the blocking system, primary antibody specificity, antibody concentration, secondary antibody cross-reactivity, and membrane-washing conditions should be further examined. Blocking solutions mainly control nonspecific adsorption at interfaces and cannot compensate for insufficient intrinsic antibody specificity.

10.3 Persistently Elevated Blank Wells in ELISA

When Blank OD remains elevated, inadequate blocking, insufficient plate washing, nonspecific adsorption of enzyme-labeled conjugates, and substrate contamination need to be distinguished. If changing the blocking agent does not markedly improve background, washing and detection-antibody conditions should be prioritized for investigation.

10.4 Positive Staining in IHC No-Primary-Antibody Controls

If DAB deposition still appears in a no-primary-antibody control in an HRP system, insufficient endogenous Peroxidase blocking and nonspecific reactions of the detection system should be investigated first. If the background is concentrated in erythrocyte-rich regions, endogenous enzyme activity should be given particular consideration.

Table 5 Blocking Selection for Different Immunoassays

11 Products Related to Immunoassay Blocking and Background Control

11.1 Protein-Based, Protein-Free, and Rapid Blocking Products

11.2 UltraBio™ Buffer-System Blocking Products

11.3 ELISA Blocking and Microplate Background-Control Products

11.4 IHC, IF, and Endogenous Enzyme Blocking Products

11.5 Fc Receptor and Immunoassay Interference Blocking Products

11.6 Washing, Antibody Dilution, and Background-Control Support Products

The core of immunoassay blocking is not to select the reagent with the “strongest blocking capacity,” but to establish a matched control system according to the actual source of background. WB and ELISA mainly address nonspecific adsorption on solid surfaces, IHC and IF additionally require consideration of the tissue environment, permeabilization, and Fc receptors, whereas HRP- and AP-based assays require separate control of the corresponding endogenous enzyme activities.

For more related articles, please see below:

[1] How long does the BSA stay closed at room temperature?

[2] Which is a better sealer, mouse sealer CD16/32 or unmodified mouse whole lgG antibody?

[3] How does the sealer work?

[4] Immunopeptide blocking assay